SEARCH

SEARCH BY CITATION

References

  • 1
    Deleuran BW, Chu CQ, Field M, Brennan FM, Katsiki P, Feldmann M, Maini RN: Localization of interleukin-1α, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol 31: 801809, 1992
  • 2
    Farahat MN, Yanni G, Poston R, Panayi GS: Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 52: 870875, 1993
  • 3
    Eastgate JA, Symons JA, Wood NC, Grinlinton FM, Di Giovine FS, Duff GW: Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 24ii: 706709, 1988
  • 4
    Westacott CI, Whicher JT, Barnes IC, Thompson D, Swan AJ, Dieppe PA: Synovial fluid concentration of five different cytokines in rheumatic diseases. Ann Rheum Dis 49ii: 676681, 1990
  • 5
    Feldmann M, Brennan FM, Chantry D, Haworth C, Turner M, Abney E, Buchan G, Barrett K, Barkley D, Chu A, Field M, Maini RN: Cytokine production in the rheumatoid joint: implications for treatment. Ann Rheum Dis 49: 480486, 1990
  • 6
    Dingle JT, Page Thomas DP, Hazleman B: The role of cytokines in arthritic diseases: in vitro and in vivo measurements of cartilage degradation. Int J Tissue React 9: 349354, 1987
  • 7
    Shinmei M, Masuda K, Kikuchi T, Shimomura Y: Interleukin 1, tumor necrosis factor, and interleukin 6 as mediators of cartilage destruction. Semin Arthritis Rheum 18: 2732, 1989
  • 8
    Brennan FM, Chantry D, Jackson A, Maini RN, Feldmann M: Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 65ii: 244247, 1989
  • 9
    Guerne PA, Carson DA, Lotz M: IL-6 production by human articular chondrocytes: modulation of its synthesis by cytokines, growth factors, and hormones in vitro. J Immunol 144: 499505, 1990
  • 10
    Guerne PA, Zuraw BL, Vaughan JH, Carson DA, Lotz M: Synovium as a source of interleukin 6 in vitro contribution to local and systemic manifestations of arthritis. J Clin Invest 83: 585592, 1989
  • 11
    Nietfeld JJ, Wilbrink B, Helle M, van Roy JLAM, den Otter RW, Swaak AJG, Huber-Bruning O: Interleukin-1-induced interleukin-6 is required for the inhibition of proteoglycan synthesis by interleukin-1 in human articular cartilage. Arthritis Rheum 33: 16951701, 1990
  • 12
    Dingle JT, Page Thomas DP, King B, Bard DR: In vivo studies of articular tissue damage mediated by catabolin/interleukin 1. Ann Rheum Dis 46: 527533, 1987
  • 13
    Van de Loo AAJ, van den Berg WB: Effects of murine recombinant interleukin 1 on synovial joints in mice: measurements of patellar cartilage metabolism and joint inflammation. Ann Rheum Dis 49: 238245, 1990
  • 14
    Henderson B, Pettipher ER: Arthritogenic actions of recombinant IL-1 and tumour necrosis factor α in the rabbit: evidence for synergistic interactions between cytokines in vivo. Clin Exp Immunol 75: 306310, 1989
  • 15
    O'Byrne EM, Blancuzzi V, Wilson DE, Wong M, Jeng AY: Elevated substance P and accelerated cartilage degradation in rabbit knees injected with interleukin-1 and tumor necrosis factor. Arthritis Rheum 33: 10231028, 1990
  • 16
    Saklatvala J: Tumour necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 322: 547549, 1986
  • 17
    Pratta MA, Di Meo TM, Ruhl DM, Arner EC: Effects of IL-1β and tumor necrosis factor α on cartilage proteoglycan metabolism in vitro. Agents Actions 27: 250253, 1989
  • 18
    Wooley PH, Whalen JD, Chapman DL, Berger AE, Richard KA, Aspar DG, Staite ND: The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum 36: 13051314, 1993
  • 19
    Van den Berg WB, Joosten LAB, Helsen MMA, van de Loo FAJ: Amelioration of established murine collagen induced arthritis with anti-IL-1 treatment. Clin Exp Immunol 95: 237243, 1994
  • 20
    Williams RO, Feldmann M, Maini RN: Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 89: 97849788, 1992
  • 21
    Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W: Evolution of collagen arthritis is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. J Immunol 77: 510514, 1992
  • 22
    Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA: involvement of endogenous tumor necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A 89: 73757379, 1992
  • 23
    Wooley PH, Dutcher J, Widmer MB, Gillis S: Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 151: 66026607, 1993
  • 24
    Brackertz D, Mitchell GF, Mackay IR: Antigen-induced arthritis in mice. I. Induction of arthritis in various strains of mice. Arthritis Rheum 20: 841850, 1977
  • 25
    Keystone EC, Schorlemmer HU, Pope C, Allison AC: Zymosan-induced arthritis: a model of chronic proliferative arthritis following activation of the alternative pathway of complement. Arthritis Rheum 20: 13961401, 1977
  • 26
    Von Asmuth EJU, Maessen JG, van der Linden CJ, Buurman WA: Tumour necrosis factor (TNF-α) and interleukin 6 in a zymosan-induced shock model. Scand J Immunol 32: 313319, 1990
  • 27
    Erdö F, Török K, Székely JI: Measurement of interleukin-1 liberation in zymosan air-pouch exudate in mice. Agents Actions 41: 9395, 1994
  • 28
    Hogquist KA, Nett MA, Sheehan KCF, Pendleton KD, Schreiber RD, Chaplin DD: Generation of monoclonal antibodies to murine IL-1β and demonstration of IL-1 in vivo. J Immunol 146: 15341540, 1991
  • 29
    Farndale RW, Buttle DJ, Barrett AJ: Improved quantitation of sulfated glycosaminoglycans by use of dimethylmethylene blue. Biochem Biophys Acta 883: 173177, 1986
  • 30
    Pettipher ER, Higgs Henderson B: Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci U S A 83: 87498753, 1986
  • 31
    Ito A, Itoh Y, Sasaguri Y, Morimatsu M, Mori Y: Effects of interleukin-6 on the metabolism of connective tissue components in rheumatoid synovial fibroblasts. Arthritis Rheum 35: 11971201, 1992
  • 32
    Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, Woody JN: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 36: 16811690, 1993
  • 33
    Lewthwaite JC, Hardingham TE, Henderson B: Interleukin-1 receptor antagonist blocks interleukin-1-induced synovitis, but not antigen-induced arthritis in the rabbit (abstract). Br J Rheumatol 31 (suppl 2): 114, 1992
  • 34
    Lewthwaite JC, Blake SM, Hardingham TE, Warden PJ, Henderson B: The effect of recombinant human interleukin 1 receptor antagonist on the induction phase of antigen-induced arthritis in the rabbit. J Rheumatol 21: 467472, 1994
  • 35
    Smith RJ, Chin JE, Sam LM, Justen JM: Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1-stimulated cartilage erosion and chondrocyte responsiveness. Arthritis Rheum 34: 7883, 1991
  • 36
    Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB: Amelioration of established collagen-induced arthritis (CIA) with anti-IL-1. Agents Actions 41: C147C176, 1994